HTACG Data Transparency and NICE Prioritisation Overhaul

Episode 15 — 25 May 2026 HTACG publishes crucial data transparency principles distinguishing commercially confidential information for joint clinical assessments. NICE launches unified prioritisation framework with eight principles from public dialogue, while EMA approves challenging orphan medicines and EFPIA raises MFN pricing access concerns. Hosted by Marcus and Sara. Outcomes Analytica Podcast — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast

Transcript

SPEAKER_00 0:00

The HTACG Data Transparency Principles published May 18th finally address the elephant in the room for JCA submissions. Trade secrets, chemical analytics, development plans stay confidential. Clinical trial methodologies and results don't qualify as commercially confidential. This distinction will fundamentally reshape how we structure evidence packages.

SPEAKER_01 0:21

About time. But I'm watching how companies interpret development plans as confidential. There's room for strategic positioning here. If your comparator strategy or endpoint rationale sits within development planning, you might shield critical commercial positioning from competitors while still meeting transparency requirements.

SPEAKER_00 0:39

Fair point. The real test comes when we see first submissions under these principles. The clarity on clinical methodologies being non-confidential means we can't hide behind proprietary claims for study design choices anymore. Every endpoint selection, every population definition becomes transparent to competitors.

SPEAKER_01 1:00

Which actually strengthens the evidence base. When methodology transparency is mandatory, companies invest more upfront in robust study design rather than hoping to explain away weaknesses and confidential annexes. This should improve overall JCA quality.

SPEAKER_00 1:14

NICE's unified prioritization framework represents an equally significant shift. Eight principles derived from public dialogue consolidated through a senior-level prioritization board. The emphasis on broader evidence definitions and proactive evidence creation direction means they're not just reacting to submissions anymore.

SPEAKER_01 1:34

The proactive evidence creation piece is crucial for our planning cycles. If NICE signals priority areas before industry develops evidence packages, we can align early stage studies with their requirements rather than retrofitting data for unexpected priorities. Strategic advantage for companies that engage early with this framework.

SPEAKER_00 1:52

27 companies registered as early adopters for the NICEMHRA aligned pathway tells you how seriously industry takes integrated assessment. Single entry consultations through their integrated scientific advice service address regulatory and value assessment conflicts at source.

SPEAKER_01 2:09

The endpoint and patient population alignment is where this pathway delivers real value. How many times have we seen MHRA accept a surrogate endpoint that nice later questions for economic evaluation? Integrated advice prevents those disconnects before they derail market access timelines.